XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SHARE-BASED COMPENSATION PLANS | 12 Months Ended
--- | ---
Dec. 31, 2023
SHARE-BASED COMPENSATION PLANS |
SHARE-BASED COMPENSATION PLANS | 19. SHARE-BASED COMPENSATION PLAN At December 31, 2023 we had one share-based compensation plan, entitled the 2017 Incentive Plan (hereinafter, “the Plan”). Under the Plan, options to purchase common stock are granted to officers and key employees at exercise prices not less than the fair market value of our Company’s common stock on the date of the grant. We also grant restricted stock awards under the Plan. We issue new common stock to satisfy stock option exercises as well as the issuance of restricted stock awards. Stock options and restricted stock awards were granted in both 2023 and 2022. Stock options and restricted stock awards are valued at fair market value based on the Company’s closing stock price on the date of grant. Stock options granted in 2023 and 2022 vest ratably over five years and expire 10 years from the grant date. Restricted stock granted in 2023 and 2022 vests ratably over four years. As of December 31, 2023, there were approximately 92,000 shares remaining available for share-based awards under the Plan. Stock option exercises can be net share settled such that we withhold shares with value equivalent to the exercise price of the stock option awards plus the employees’ minimum statutory obligation for the applicable income and other employment taxes. The net share settlement has the effect of share repurchases by the Company as they reduce the number of shares that would have otherwise been issued. In 2023, approximately 430,000 shares were withheld, and were based on the value of the stock on the exercise dates. Total payments made by the Company for the employees’ tax obligations to the taxing authorities were $186,000 in 2023 and $12,000 in 2022; such payments are generally reflected as a financing activity within the consolidated statements of cash flows. In accordance with ASC 718, share-based compensation expense of approximately $1.4 million and $1.5 million was recognized in 2023 and 2022, respectively, for stock options and restricted stock awards granted since 2017. An estimate of forfeitures, based on historical data, was included in the calculation of share-based compensation. At December 31, 2023, there was $2.1 million of total unrecognized compensation cost related to non-vested stock options granted in the years 2019 through 2023 which is expected to be recognized over the weighted-average remaining vesting period of 3.7 years. At December 31, 2022, there was $1.8 million of total unrecognized compensation cost related to non-vested stock options granted in the years 2018 through 2022 which was expected to be recognized over the weighted-average remaining vesting period of 3.7 years. The following weighted-average assumptions were used to determine compensation expense related to stock options in 2023 and 2022: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022 |
Risk-free interest rate |  | 4.31 | % | 3.08 | %
Expected dividend yield |  | 3.88 | % | 3.33 | %
Expected term |  | 8.0 |  | 8.0 | ​
Expected volatility |  | 31.0 | % | 28.5 | %
​ The risk-free interest rate is based on U.S. Treasury bonds with a remaining term equal to the expected term of the award. The expected dividend yield is based on our expected annual dividend as a percentage of the market value of our Company’s common stock in the year of grant. The expected term of the stock options is determined using historical experience. The expected volatility is based upon historical stock prices over the most recent period equal to the expected term of the award. The following tables summarize our stock option activity during the years ended December 31, 2023 and 2022: Stock Options ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Years ended December 31,
​ | ​ | 2023 | ​ | 2022
​ | ​ | ​ | ​ | ​ | Weighted Average | ​ | ​ | ​ | ​ | Weighted Average
Stock Options |  | Shares |  | Exercise Price |  | Shares |  | Exercise Price
Outstanding at beginning of year | ​ | ​ | 1,345,369 | ​ | $ | 25.83 | ​ | ​ | 1,279,833 | ​ | $ | 25.44
Granted |  | ​ | 149,200 |  | ​ | 25.79 |  | ​ | 143,500 |  | ​ | 28.83
Exercised |  | ​ | (487,331) |  | ​ | 25.02 |  | ​ | (60,914) |  | ​ | 24.96
Forfeited or expired |  | ​ | (40,021) |  | ​ | 26.31 |  | ​ | (17,050) |  | ​ | 24.79
Outstanding at end of year |  | ​ | 967,217 | ​ | $ | 26.22 |  | ​ | 1,345,369 | ​ | $ | 25.83
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercisable at end of year |  | ​ | 524,829 | ​ | $ | 27.30 |  | ​ | 891,733 | ​ | $ | 26.36
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average fair market value of options granted | ​ | $ | 6.63 | ​ | ​ | ​ |  | $ | 6.78 | ​ | ​ | ​
​
​ | ​ | ​ | ​ | ​ | ​
​ |  | Weighted Average Remaining |  | ​ | ​
​ | ​ | Contractual Life (in Years) | ​ | Aggregate Intrinsic Value
Outstanding - December 31, 2023 |  | 6.7 | ​ | $ | 5,649,000
Exercisable - December 31, 2023 |  | 5.4 | ​ | $ | 2,804,000
​ The aggregate intrinsic value of outstanding and exercisable stock options is defined as the difference between the market value of our Company’s common stock on December 29, 2023 of $31.36 and the exercise price multiplied by the number of in-the-money outstanding and exercisable stock options. Non-vested Stock Options ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted Average | ​ | Weighted Average
​ | ​ | Number of Options | ​ | Exercise Price | ​ | Fair Value
Non-vested - December 31, 2021 | ​ | 511,311 | ​ | $ | 23.63 | ​ | $ | 3.64
Granted | ​ | 143,500 | ​ |  | 28.83 | ​ |  | 6.78
Vested | ​ | (189,375) | ​ |  | 25.08 | ​ |  | 3.87
Forfeited | ​ | (11,800) | ​ |  | 23.20 | ​ |  | 3.65
Non-vested - December 31, 2022 | ​ | 453,636 | ​ | $ | 24.76 | ​ | $ | 4.55
Granted | ​ | 149,200 | ​ |  | 25.79 | ​ |  | 6.63
Vested | ​ | (147,128) | ​ |  | 25.26 | ​ |  | 4.44
Forfeited | ​ | (13,320) | ​ |  | 25.24 | ​ |  | 4.91
Non-vested - December 31, 2023 | ​ | 442,388 | ​ | $ | 24.93 | ​ | $ | 5.28
​ The following table summarizes information about outstanding and exercisable stock options at December 31, 2023:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Options Outstanding | ​ | Options Exercisable
​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Number of | ​ | Remaining | ​ | Weighted | ​ | Number of | ​ | Weighted
​ | ​ | Options | ​ | Contractual Life | ​ | Average | ​ | Options | ​ | Average
Range of Exercise Prices |  | Outstanding |  | (in Years) |  | Exercise Price |  | Exercisable |  | Exercise Price
$18.00 | ​ | 134,760 | ​ | 6.7 | ​ | $ | 18.00 | ​ | 74,260 | ​ | $ | 18.00
$23.38 to $25.79 |  | 432,695 |  | 7.8 | ​ | $ | 24.43 |  | 160,415 | ​ | $ | 23.65
$27.94 to $37.22 |  | 399,762 |  | 5.7 | ​ | $ | 30.92 |  | 290,154 | ​ | $ | 31.70
​ |  | 967,217 |  | 6.7 | ​ | $ | 26.22 |  | 524,829 | ​ | $ | 27.30
​ The following table summarizes our stock option activity for the years ended December 31:
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2023 |  | 2022
​ | ​ | (Dollars in thousands)
Total intrinsic value of stock options exercised | ​ | $ | 1,537 | ​ | $ | 251
Net proceeds from stock option exercises | ​ | $ | 103 | ​ | $ | 293
Income tax benefit from the exercise of stock options | ​ | $ | 400 | ​ | $ | 65
Total fair value of stock options vested | ​ | $ | 653 | ​ | $ | 734
​ Restricted Stock The following table summarizes our restricted stock award activity during the years ended December 31, 2022 and 2023:
​ | ​ | ​ | ​ | ​ | ​
​ |  | Shares of Restricted |  | Weighted Average
​ | ​ | Stock | ​ | Grant Date Fair Value
Non-vested - December 31, 2021 |  | 78,470 | ​ | $ | 23.11
Issued |  | 27,620 | ​ |  | 28.83
Vested |  | (34,282) | ​ |  | 24.46
Forfeited | ​ | — | ​ |  | —
Non-vested - December 31, 2022 |  | 71,808 | ​ | $ | 24.67
Issued |  | 27,700 | ​ |  | 25.79
Vested |  | (28,243) | ​ |  | 23.60
Forfeited |  | (2,175) | ​ |  | 25.13
Non-vested - December 31, 2023 | ​ | 69,090 | ​ | $ | 25.54
​ At December 31, 2023, we expected 69,090 shares of restricted stock to vest over a weighted-average remaining contractual term of 2.7 years. These shares had an aggregate intrinsic value of $2.2 million at December 31, 2023. The aggregate intrinsic value was calculated using the market value of our Company’s common stock on December 29, 2023 of $31.36 multiplied by the number of non-vested restricted shares outstanding. The income tax benefit from the vesting of restricted stock for the years ended December 31 was $188,000 in 2023 and $247,000 in 2022.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration